Filing Flows › Lenz Therapeutics (LENZ) › Who owns the stock
Who owns Lenz Therapeutics (LENZ) stock
133 funds reported Lenz Therapeutics (LENZ) shares in their latest 13F filings, worth $210M in all. The largest holder is RA Capital Management, L.P. ($23.7M). Last quarter 80 funds added to their stakes and 54 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| RA Capital Management, L.P. | 4,178,823 | $23.7M | unchanged | 2026-06-30 |
| Vanguard Group | 1,321,202 | $21.1M | decrease | 2025-12-31 |
| Alpha Wave Global, LP | 3,612,211 | $20.5M | unchanged | 2026-06-30 |
| FMR LLC | 3,558,905 | $20.2M | decrease | 2026-06-30 |
| Versant Venture Management, LLC | 2,656,888 | $15.1M | unchanged | 2026-06-30 |
| BlackRock | 2,292,121 | $13.0M | increase | 2026-06-30 |
| Squarepoint Ops LLC | 1,747,096 | $9.9M | increase | 2026-06-30 |
| abrdn | 1,547,883 | $8.8M | increase | 2026-06-30 |
| Millennium Management LLC | 1,508,478 | $8.6M | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 1,097,755 | $6.2M | increase | 2026-06-30 |
| 72 Investment Holdings, LLC | 1,017,751 | $5.8M | unchanged | 2026-06-30 |
| Geode Capital Management, LLC | 564,662 | $3.2M | increase | 2026-06-30 |
| Trexquant Investment LP | 497,526 | $2.8M | increase | 2026-06-30 |
| Marshall Wace, LLP | 493,099 | $2.8M | increase | 2026-06-30 |
| Qube Research & Technologies | 482,195 | $2.7M | new | 2026-06-30 |
Lenz Therapeutics' latest quarter
Lenz Therapeutics, Q3 2026: revenue $3.4M (-73% year over year), operating margin -972.8%, net loss $31.0M, operating cash flow −$22.3M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most LENZ stock?
By the latest 13F filings: RA Capital Management, L.P. ($23.7M); Vanguard Group ($21.1M); Alpha Wave Global, LP ($20.5M); FMR LLC ($20.2M); Versant Venture Management, LLC ($15.1M).
What is the short interest in LENZ?
9,095,817 shares were sold short at the 2026-10-15 settlement, -13.87% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.